Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 2
1963 1
1964 2
1965 2
1967 3
1968 4
1969 1
1970 1
1971 1
1972 2
1973 5
1974 1
1975 2
1976 2
1977 3
1978 4
1979 17
1980 16
1981 18
1982 18
1983 21
1984 17
1985 13
1986 23
1987 25
1988 36
1989 25
1990 30
1991 30
1992 25
1993 38
1994 30
1995 26
1996 38
1997 39
1998 47
1999 37
2000 31
2001 36
2002 37
2003 43
2004 52
2005 56
2006 54
2007 55
2008 38
2009 56
2010 42
2011 48
2012 60
2013 56
2014 57
2015 61
2016 82
2017 71
2018 66
2019 79
2020 106
2021 95
2022 103
2023 12
Text availability
Article attribute
Article type
Publication date

Search Results

1,851 results
Results by year
Filters applied: . Clear all
Page 1
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant.
Suzuki R, Yamasoba D, Kimura I, Wang L, Kishimoto M, Ito J, Morioka Y, Nao N, Nasser H, Uriu K, Kosugi Y, Tsuda M, Orba Y, Sasaki M, Shimizu R, Kawabata R, Yoshimatsu K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sawa H, Ikeda T, Irie T, Matsuno K, Tanaka S, Fukuhara T, Sato K. Suzuki R, et al. Among authors: tsuda m. Nature. 2022 Mar;603(7902):700-705. doi: 10.1038/s41586-022-04462-1. Epub 2022 Feb 1. Nature. 2022. PMID: 35104835 Free PMC article.
Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike.
Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, Uriu K, Tsuda M, Zahradnik J, Shirakawa K, Suzuki R, Kishimoto M, Kosugi Y, Kobiyama K, Hara T, Toyoda M, Tanaka YL, Butlertanaka EP, Shimizu R, Ito H, Wang L, Oda Y, Orba Y, Sasaki M, Nagata K, Yoshimatsu K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Kuramochi J, Seki M, Fujiki R, Kaneda A, Shimada T, Nakada TA, Sakao S, Suzuki T, Ueno T, Takaori-Kondo A, Ishii KJ, Schreiber G; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sawa H, Saito A, Irie T, Tanaka S, Matsuno K, Fukuhara T, Ikeda T, Sato K. Yamasoba D, et al. Among authors: tsuda m. Cell. 2022 Jun 9;185(12):2103-2115.e19. doi: 10.1016/j.cell.2022.04.035. Epub 2022 May 2. Cell. 2022. PMID: 35568035 Free PMC article.
Specification of CNS macrophage subsets occurs postnatally in defined niches.
Masuda T, Amann L, Monaco G, Sankowski R, Staszewski O, Krueger M, Del Gaudio F, He L, Paterson N, Nent E, Fernández-Klett F, Yamasaki A, Frosch M, Fliegauf M, Bosch LFP, Ulupinar H, Hagemeyer N, Schreiner D, Dorrier C, Tsuda M, Grothe C, Joutel A, Daneman R, Betsholtz C, Lendahl U, Knobeloch KP, Lämmermann T, Priller J, Kierdorf K, Prinz M. Masuda T, et al. Among authors: tsuda m. Nature. 2022 Apr;604(7907):740-748. doi: 10.1038/s41586-022-04596-2. Epub 2022 Apr 20. Nature. 2022. PMID: 35444273
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Kang YK, et al. Among authors: tsuda m. Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6. Lancet. 2017. PMID: 28993052 Clinical Trial.
XRCC1 prevents toxic PARP1 trapping during DNA base excision repair.
Demin AA, Hirota K, Tsuda M, Adamowicz M, Hailstone R, Brazina J, Gittens W, Kalasova I, Shao Z, Zha S, Sasanuma H, Hanzlikova H, Takeda S, Caldecott KW. Demin AA, et al. Among authors: tsuda m. Mol Cell. 2021 Jul 15;81(14):3018-3030.e5. doi: 10.1016/j.molcel.2021.05.009. Epub 2021 Jun 7. Mol Cell. 2021. PMID: 34102106 Free PMC article.
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).
Boku N, Ryu MH, Kato K, Chung HC, Minashi K, Lee KW, Cho H, Kang WK, Komatsu Y, Tsuda M, Yamaguchi K, Hara H, Fumita S, Azuma M, Chen LT, Kang YK. Boku N, et al. Among authors: tsuda m. Ann Oncol. 2019 Feb 1;30(2):250-258. doi: 10.1093/annonc/mdy540. Ann Oncol. 2019. PMID: 30566590 Free PMC article. Clinical Trial.
The liver-brain-gut neural arc maintains the Treg cell niche in the gut.
Teratani T, Mikami Y, Nakamoto N, Suzuki T, Harada Y, Okabayashi K, Hagihara Y, Taniki N, Kohno K, Shibata S, Miyamoto K, Ishigame H, Chu PS, Sujino T, Suda W, Hattori M, Matsui M, Okada T, Okano H, Inoue M, Yada T, Kitagawa Y, Yoshimura A, Tanida M, Tsuda M, Iwasaki Y, Kanai T. Teratani T, et al. Among authors: tsuda m. Nature. 2020 Sep;585(7826):591-596. doi: 10.1038/s41586-020-2425-3. Epub 2020 Jun 11. Nature. 2020. PMID: 32526765
Astrocytic phagocytosis is a compensatory mechanism for microglial dysfunction.
Konishi H, Okamoto T, Hara Y, Komine O, Tamada H, Maeda M, Osako F, Kobayashi M, Nishiyama A, Kataoka Y, Takai T, Udagawa N, Jung S, Ozato K, Tamura T, Tsuda M, Yamanaka K, Ogi T, Sato K, Kiyama H. Konishi H, et al. Among authors: tsuda m. EMBO J. 2020 Nov 16;39(22):e104464. doi: 10.15252/embj.2020104464. Epub 2020 Sep 22. EMBO J. 2020. PMID: 32959911 Free PMC article.
1,851 results